The Trump administration has announced that US military personnel aged 30 and over will receive annual testosterone screenings, with voluntary hormone replacement therapy available to those diagnosed with low testosterone.
Defence Secretary Pete Hegseth unveiled the Pentagon initiative, branding it the “High-T Department of War”.
Hegseth argued that screening and treatment would help ensure service members were operating at their “absolute best” by identifying testosterone deficiencies and providing appropriate medical care.
Initiative Draws Accusations of Hypocrisy
The announcement was met with immediate criticism, although much of the backlash was not directed at testosterone therapy itself.
Instead, critics highlighted the contrast between the initiative and the administration’s efforts to restrict gender-affirming healthcare for transgender people and remove transgender personnel from the US military.
LGBTQIA+ advocates said the policy demonstrated that hormone therapy is accepted when offered to cisgender service members, despite similar treatments being politically targeted when accessed by transgender people.
Gender-affirming healthcare is a broad term covering medical care that helps people feel comfortable with their bodies and gender presentation.
For transgender people, that care can include hormone treatment, puberty blockers and surgery.
For cisgender people, it can include testosterone replacement therapy for clinically low testosterone, oestrogen treatment during menopause, breast reconstruction after cancer, erectile dysfunction treatment, fertility care and medication for hair loss.
Some cosmetic procedures may also be considered gender affirming when they help a person create, restore or emphasise physical characteristics connected to their gender presentation.
That can include treatments such as Botox, lip fillers and other cosmetic procedures intended to help someone feel more confident or comfortable with their appearance.
In practice, both transgender and cisgender people receive forms of gender-affirming healthcare every year, although the term is most commonly used in public debate when discussing transgender patients.
Democratic Lawmakers Question Administration’s Position
Democratic politicians were quick to point out what they saw as an inconsistency in the administration’s approach.
Senator Tammy Duckworth responded that the military initiative “sounds like gender-affirming care to me”.
Representative Summer Lee also questioned whether the administration now supported the same category of healthcare it had previously sought to restrict.
SPARTA Pride, an organisation representing transgender service members and veterans, said the policy exposed a contradiction in how hormone therapy was being treated.
“If hormone therapy helps warfighters perform at their best, then it cannot simultaneously be used as evidence that transgender service members are unfit to serve,” executive director Kara Corcoran told the Washington Blade. “The same class of evidence-based medical treatment cannot be characterised as readiness-enhancing for one group and readiness-destroying for another.”
Advocates argue that the Pentagon initiative reinforces their view that the political dispute has never been solely about hormone treatment or medical risk.
Instead, they say the controversy has centred on which patients are permitted to receive that care and whether transgender people should have equal access to evidence-based treatment.
